NASDAQ:NDRA ENDRA Life Sciences Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding ENDRA Life Sciences Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $0.23 0.00 (-1.84%) (As of 07/1/2022 03:58 PM ET) Add Compare Share Today's Range$0.22▼$0.2350-Day Range$0.19▼$0.2852-Week Range$0.18▼$2.22Volume2,310 shsAverage Volume1.67 million shsMarket Capitalization$10.14 millionP/E RatioN/ADividend YieldN/APrice Target$5.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media ENDRA Life Sciences Stock Forecast (MarketRank)Analyst RatingBuy3.00 Rating ScoreUpside/Downside2,073.9% Upside$5.00 Price TargetShort InterestHealthy0.97% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.82Based on 4 Articles This WeekInsider TradingAcquiring Shares$11.72 K Bought Last QuarterProj. Earnings GrowthGrowingFrom ($0.19) to ($0.09) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.2.00 out of 5 starsMedical Sector488th out of 1,429 stocksElectromedical Equipment Industry13th out of 30 stocks 3.5 Analyst's Opinion Consensus RatingENDRA Life Sciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $5.00, ENDRA Life Sciences has a forecasted upside of 2,073.9% from its current price of $0.23.Amount of Analyst CoverageENDRA Life Sciences has only been the subject of 1 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.97% of the outstanding shares of ENDRA Life Sciences have been sold short.Short Interest Ratio / Days to CoverENDRA Life Sciences has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in ENDRA Life Sciences has recently decreased by 55.04%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldENDRA Life Sciences does not currently pay a dividend.Dividend GrowthENDRA Life Sciences does not have a long track record of dividend growth. Previous Next 0.0 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for NDRA. Previous Next 2.7 News and Social Media Coverage News SentimentENDRA Life Sciences has a news sentiment score of 0.82. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for ENDRA Life Sciences this week, compared to 1 article on an average week.Search Interest7 people have searched for NDRA on MarketBeat in the last 30 days. This is an increase of 75% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added ENDRA Life Sciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, ENDRA Life Sciences insiders have bought more of their company's stock than they have sold. Specifically, they have bought $11,719.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 6.30% of the stock of ENDRA Life Sciences is held by insiders.Percentage Held by InstitutionsOnly 10.03% of the stock of ENDRA Life Sciences is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for ENDRA Life Sciences are expected to grow in the coming year, from ($0.19) to ($0.09) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ENDRA Life Sciences is -0.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ENDRA Life Sciences is -0.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioENDRA Life Sciences has a P/B Ratio of 0.92. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive NDRA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ENDRA Life Sciences and its competitors with MarketBeat's FREE daily newsletter. Email Address About ENDRA Life Sciences (NASDAQ:NDRA)ENDRA Life Sciences Inc. develops technology for improving the capabilities of clinical diagnostic ultrasound. The company develops thermo-acoustic enhanced ultrasound technology that transmits sound waves, which bounce off tissues, organs, and blood in the body for use in the treatment of nonalcoholic fatty liver disease, as well as in temperature monitoring of thermoablative surgery, vascular imaging, and tissue perfusion. It also offers diagnostic imaging technologies, such as computed tomography, magnetic resonance imaging, and ultrasound that allow physicians to look inside a person's body to guide treatment or gather information about medical conditions, such as broken bones, cancers, signs of heart disease, or internal bleeding. The company has a collaborative research agreement with General Electric Company. ENDRA Life Sciences Inc. was incorporated in 2007 and is based in Ann Arbor, Michigan.Read More NDRA Stock News HeadlinesJune 28, 2022 | seekingalpha.comENDRA Life Sciences rises on new U.S. patent for liver disease monitoring systemJune 28, 2022 | finance.yahoo.comENDRA Life Sciences Enhances TAEUS® System Intellectual Property Portfolio with Issuance of 28th U.S. PatentJune 24, 2022 | apnews.comLife and Health Reinsurance Global Market Report 2022 - ResearchAndMarkets.comJune 15, 2022 | bizjournals.comTriangle falls outside top 5 markets for life sciences workforce, report saysJune 15, 2022 | americanbankingnews.comHead to Head Survey: ENDRA Life Sciences (NASDAQ:NDRA) and Electromed (NYSE:ELMD)June 13, 2022 | msn.comLife sciences news: New startups, fundings, mergers, clinical trials, partnershipsJune 8, 2022 | finance.yahoo.comENDRA Life Sciences to Participate in the JMP Securities Life Sciences ConferenceJune 8, 2022 | americanbankingnews.comENDRA Life Sciences (NASDAQ:NDRA) Lifted to Buy at Zacks Investment ResearchMay 25, 2022 | finance.yahoo.comENDRA Life Sciences Bolsters TAEUS® System Intellectual Property with Issuance of 27th U.S. PatentMay 16, 2022 | finance.yahoo.comENDRA Life Sciences to Present at the H.C. Wainwright Global Investment ConferenceMay 13, 2022 | investing.comENDRA Life Sciences Reports In-Line Q1 EPSMay 13, 2022 | benzinga.comENDRA Life Sciences: Q1 Earnings InsightsMay 13, 2022 | seekingalpha.comEndra Life Sciences GAAP EPS of -$0.07See More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Electromedical equipment Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:NDRA CUSIPN/A CIK1681682 Webwww.endrainc.com Phone(734) 335-0468FaxN/AEmployees18Year FoundedN/ACompany Calendar Last Earnings11/15/2021Today7/01/2022Next Earnings (Estimated)8/11/2022Fiscal Year End12/31/2022Price Target and Rating Average Stock Price Forecast$5.00 High Stock Price Forecast$5.00 Low Stock Price Forecast$5.00 Forecasted Upside/Downside+2,073.9%Consensus RatingBuy Rating Score (0-4)3 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.280010) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-11.23 million Net MarginsN/A Pretax MarginN/A Return on Equity-98.50% Return on Assets-83.88% Debt Debt-to-Equity RatioN/A Current Ratio7.45 Quick Ratio6.03 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.25 per share Price / Book0.92Miscellaneous Outstanding Shares44,089,000Free Float41,311,000Market Cap$10.14 million OptionableNot Optionable Beta1.40 ENDRA Life Sciences Frequently Asked Questions Should I buy or sell ENDRA Life Sciences stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ENDRA Life Sciences in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" ENDRA Life Sciences stock. View analyst ratings for ENDRA Life Sciences or view top-rated stocks. What is ENDRA Life Sciences' stock price forecast for 2022? 1 brokerages have issued 12 month price targets for ENDRA Life Sciences' shares. Their NDRA stock forecasts range from $5.00 to $5.00. On average, they expect ENDRA Life Sciences' stock price to reach $5.00 in the next twelve months. This suggests a possible upside of 2,073.9% from the stock's current price. View analysts' price targets for ENDRA Life Sciences or view top-rated stocks among Wall Street analysts. How has ENDRA Life Sciences' stock price performed in 2022? ENDRA Life Sciences' stock was trading at $0.6918 at the beginning of the year. Since then, NDRA shares have decreased by 66.8% and is now trading at $0.23. View the best growth stocks for 2022 here. When is ENDRA Life Sciences' next earnings date? ENDRA Life Sciences is scheduled to release its next quarterly earnings announcement on Thursday, August 11th 2022. View our earnings forecast for ENDRA Life Sciences. How were ENDRA Life Sciences' earnings last quarter? ENDRA Life Sciences Inc. (NASDAQ:NDRA) issued its quarterly earnings results on Monday, November, 15th. The company reported ($0.06) EPS for the quarter, topping the consensus estimate of ($0.07) by $0.01. During the same quarter in the previous year, the firm earned ($0.15) earnings per share. View ENDRA Life Sciences' earnings history. Who are ENDRA Life Sciences' key executives? ENDRA Life Sciences' management team includes the following people: Mr. Francois Michelon, Chairman, Pres & CEO (Age 56, Pay $511.64k)Mr. Michael Thornton, Chief Technology Officer (Age 54, Pay $358.75k) (LinkedIn Profile)Mr. Renaud Bertrand Maloberti, Chief Commercial Officer (Age 53, Pay $321.53k)Dr. Jonathan Behr, Co-FounderMs. Irina Pestrikova, Sr. Director of Fin. & Sec. (Age 35)Mr. Steve Freeman, HR Leader Who are some of ENDRA Life Sciences' key competitors? Some companies that are related to ENDRA Life Sciences include IRIDEX (IRIX), Fc Global Realty (FCRE), electroCore (ECOR), Precision Optics (PEYE), BioSig Technologies (BSGM), Positron (POSC), Tivic Health Systems (TIVC), Yubo International Biotech (YBGJ), Vaso (VASO), Soleno Therapeutics (SLNO), Star Equity (STRR), Guided Therapeutics (GTHP), Micron Solutions (MICR), Viveve Medical (VIVE) and Nuwellis (NUWE). View all of NDRA's competitors. What other stocks do shareholders of ENDRA Life Sciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other ENDRA Life Sciences investors own include Advanced Micro Devices (AMD), Trevena (TRVN), VBI Vaccines (VBIV), Ampio Pharmaceuticals (AMPE), Bionano Genomics (BNGO), OPKO Health (OPK), TherapeuticsMD (TXMD), Vista Gold (VGZ), electroCore (ECOR) and Genocea Biosciences (GNCA). When did ENDRA Life Sciences IPO? (NDRA) raised $10 million in an initial public offering on Friday, February 3rd 2017. The company issued 2,000,000 shares at a price of $5.00-$5.50 per share. Dougherty & Company and Dawson James Securities acted as the underwriters for the IPO. What is ENDRA Life Sciences' stock symbol? ENDRA Life Sciences trades on the NASDAQ under the ticker symbol "NDRA." How do I buy shares of ENDRA Life Sciences? Shares of NDRA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is ENDRA Life Sciences' stock price today? One share of NDRA stock can currently be purchased for approximately $0.23. How much money does ENDRA Life Sciences make? ENDRA Life Sciences (NASDAQ:NDRA) has a market capitalization of $10.14 million. The company earns $-11.23 million in net income (profit) each year or ($0.280010) on an earnings per share basis. How many employees does ENDRA Life Sciences have? ENDRA Life Sciences employs 18 workers across the globe. How can I contact ENDRA Life Sciences? ENDRA Life Sciences' mailing address is 3600 GREEN COURT SUITE 350, ANN ARBOR MI, 48105. The official website for ENDRA Life Sciences is www.endrainc.com. The company can be reached via phone at (734) 335-0468 or via email at [email protected]. This page (NASDAQ:NDRA) was last updated on 7/1/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here
